相关实验视频

Updated: Sep 16, 2025

Neutrophil Isolation and Analysis to Determine their Role in Lymphoma Cell Sensitivity to Therapeutic Agents

Neutrophil Isolation and Analysis to Determine their Role in Lymphoma Cell Sensitivity to Therapeutic Agents

Published on: March 25, 2016

易布鲁替尼增加了慢性淋巴细胞白血病患者的白血病细胞中的miR-181a/b

Alice Ramassone¹, Sara Pagotto¹, Mirco Di Marco²

¹G. d'Annunzio University, Chieti, Italy.

|July 11, 2025

概括

治疗慢性淋巴细胞白血病 (CLL) 的易布鲁替尼增加了亲细胞灭绝的miRNAs (miR-181a/b) 并降低了c-Fos,揭示了与细胞死亡和CLL患者潜在抵抗机制相关的反循环.

科学领域:

分子生物学分子生物学
在瘤学瘤学.
遗传学遗传学是一个

背景情况:

易布鲁替尼是布鲁顿的氨酸激酶抑制剂,对慢性淋巴细胞白血病 (CLL) 有效.
尽管反应率很高,但在一些CLL患者中发生临床复发,需要了解抵抗机制.
研究易布鲁替尼影响的分子通路对于识别耐药性策略至关重要.

研究的目的:

阐明依布鲁替尼在慢性淋巴细胞白血病 (CLL) 中的影响背后的分子机制.
为了确定与ibrutinib治疗和潜在耐药性相关的特定分子变化.
探索ibrutinib治疗的CLL细胞中涉及miRNA和转录因子的调控反循环.

主要方法:

分析了来自12名慢性淋巴细胞白血病 (CLL) 患者的60个纵向样本,这些患者接受了ibrutinib治疗.
对miR-181a和miR-181b表达水平的量化.
在ibrutinib治疗后测量白细胞计数和c-Fos蛋白水平.

主要成果:

观察到miR-181a和miR-181b的表达增加,与CLL患者白细胞计数减少相关.
易布鲁替尼治疗通过转录上调了亲细胞亡的miRNAs (miR-181a/b),当细胞经历细胞亡时变得明显.
72小时后,c-Fos蛋白水平下降,被确定为miR-181a/b的调节者,并与细胞死亡建立了反循环.

结论:

易布鲁替尼诱导了一个涉及miR-181a/b和c-Fos的调控反循环,导致慢性淋巴细胞白血病 (CLL) 中的细胞死亡.
这些发现为ibrutinib在CLL中的作用机制提供了洞察力.
已确定的分子通路为研究CLL患者对ibrutinib耐药性的机制提供了基础.

更多相关视频

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Published on: October 23, 2019

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation

Published on: November 26, 2018

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Abnormal Proliferation

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...